The US and European Regulatory Systems: A Comparison

Journal of Ambulatory Care Management

Volumn 27, Issue 2, 2004, Pages 105-114

  Redmond, Kathy ^a  

^a NONE   (Italy)

Author keywords

Approval time; Cancer; Drug approval; EMEA; Fast tracking; FDA; Medicines; Regulation

Indexed keywords

ALEMTUZUMAB; ALITRETINOIN; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ARCITUMOMAB TC 99M; ARSENIC TRIOXIDE; BEXAROTENE; CALCITONIN; CAPECITABINE; CYTARABINE; DEPREOTIDE TC 99M; DOCETAXEL; DOXORUBICIN; IBANDRONIC ACID; IGOVAMAB; INDIMACIS 125; LEXIDRONAM SAMARIUM SM 153; MELANOMA ANTIBODY; PACLITAXEL; RASBURICASE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT THYROTROPIN; RITUXIMAB; SALCATONIN; TASONERMIN; TECNEMAB K1; TEMOPORFIN; TEMOZOLOMIDE; THYROTROPIN; TOPOTECAN; TOREMIFENE; TRASTUZUMAB; TRISONEX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOTUMUMAB; ZOLEDRONIC ACID;

DRUG APPROVAL; DRUG MARKETING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; REVIEW;

EID: 1642320280     PISSN: 01489917     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004479-200404000-00005     Document Type: Review

References (15)

1. Centre for Drug Evaluation and Research. (2003). CDER 2002 Report to the Nation: Improving public health through human drugs. Rockville, MD: Author. Available from http://www.fda.gov/cder/reports/rtn/2002/Rtn2002.pdf
2. Department of Health and Human Services, Code of Federal Regulations. (1999). Subpart H-Accelerated approval of new drugs for serious or life-threatening illnesses. Available from http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi?TITLE=21&PART= 314&SECTION=510&YEAR=1999&TYPE=TEXT
3. European Medicines Evaluation Agency. (1996). Position paper on how to proceed with specific obligations and follow-up measures for the management of marketing authorisation (CPMP/725/96.final). London: Author. Available from http://www.emea.eu.int/pdfs/human/press/pp/072596en.pdf
4. European Medicines Evaluation Agency. (2000). Applications in the centralised procedure - An analysis of outcomes (CPMP/602/00). London: Author. Available from http://www.emea.eu.int/pdfs/human/regaffair/060200en.pdf
5. European Medicines Evaluation Agency. (2001). Accelerated evaluation of products indicated for serious diseases (CPMP/495/96 rev 1). London: Author. Available from http://www.emea.eu.int/pdfs/human/regaffair/049596en.pdf
6. European Medicines Evaluation Agency. (2003a). The European Agency for the Evaluation of Medicinal Products: Eighth Annual Report 2002. London: Author. Available from http://www.emea.eu.int/pdfs/general/direct/emeaar/005502en.pdf
7. European Medicines Evaluation Agency. (2003b). EMEA/CPMP Therapeutic Advisory Groups: Rules of procedure (EMEA/CPMP/257/03/en final). Available from http://www.emea.eu.int/pdfs/human/therapeutic/025703en.pdf
8. European Medicines Evaluation Agency. (2003c). EMEA/CPMP Working group with patients' organisations (EMEA/CPMP/2613/03). Available from http://www.emea.eu.int/pdfs/human/patientgroup/261303en.pdf
9. Food and Drug Administration. (1996). Priority review policy. Rockville, MD: Center for Drug Evaluation and Research. Available from http://www.fda.gov/cder/mapp/6020-3.pdf
10. Food and Drug Administration. (1998). Guidance for industry: fast track drug development programs - designation, development and application review (Procedural 9). Rockville, MD: Author. Available from http://www.fda.gov/cder/guidance/2112fnl.pdf
11. Food and Drug Administration. (1999). Cancer patient representative program. Rockville, MD: Author. Available from http://www.fda.gov/oashi/cancer/cpat.html
12. Food and Drug Administration. (2001). Cancer drug development patient consultant program. Rockville, MD: Author. Available from http://www.fda.gov/oashi/cancer/pconback.html
13. Food and Drug Administration. (2002). Investigational new drug application process. Rockville, MD: Author. Available from http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm#Introduction
14. Food and Drug Administration. (2003a). Approval times for priority and standard NDAs: Calendar years 1993-2002. Rockville, MD: Author. Available from http://www.fda.gov/cder/rdmt/NMEapps93-02.htm
15. Food and Drug Administration. (2003b). NCI and FDA announce joint programs to streamline cancer drug development. Rockville, MD: Author. Available from http://www.fda.gov/bbs/topics/NEWS/2003/NEW00912.html